(Q49242773)

19 February 2018

title

Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence. (English)

1 reference

19 February 2018

0 references

Mark S Freedman

1

1 reference

19 February 2018

publication date

1 December 2011

1 reference

19 February 2018

Neurology. Clinical practice

published in

1 reference

19 February 2018

volume

1

1 reference

19 February 2018

issue

1

1 reference

19 February 2018

page(s)

66-68

1 reference

19 February 2018

Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5766179

Axonal transection in the lesions of multiple sclerosis

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5766179

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5766179

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5766179

'Time is brain' also in multiple sclerosis

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5766179

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5766179

Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F,

14 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29443288

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/CPJ.0B013E31823CC2C2

1 reference

19 February 2018

PMC publication ID

5766179

1 reference

19 February 2018

PubMed publication ID

29443288

1 reference

19 February 2018